[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

about

Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why?

P2860

Q42329924-D9326705-7347-4440-BB4E-A65DB6185CC6

P2860

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

Item

http://www.wikidata.org/entity/Q40530427

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

@en

type

Item

label

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

@en

prefLabel

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

@en

P1476

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

@en

P2093

Nan Zhu

http://www.w3.org/2001/XMLSchema#string

Xia Song

http://www.w3.org/2001/XMLSchema#string

Xiaoyan Kang

http://www.w3.org/2001/XMLSchema#string

P2860

The latest therapeutic strategies after resistance to first generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients with non-small cell lung cancer (NSCLC)

Mutation of the BRAF genes in non-small cell lung cancer

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

P304

711-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2016.10.13

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27760604

http://www.w3.org/2001/XMLSchema#string

P932

5973409

http://www.w3.org/2001/XMLSchema#string

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

about

P2860

P2860

[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932